ArticleVeterinary ophthalmology2026
Effects of Topical Omidenepag Isopropyl on Intraocular Pressure and Pupil Diameter in Normal Dogs.
Article in Veterinary ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo determine the effects of 0.002% omidenepag isopropyl (OMDI) ophthalmic solution on intraocular pressure (IOP) and pupil diameter (PD) in clinically normal dogs.
methodsFive healthy dogs (10 eyes) were included in this prospective randomized, observer-masked, placebo-controlled study. An initial pilot study was conducted to evaluate IOP and ocular irritation up to 48 h after a single instillation of OMDI. For the subsequent main study, each dog received one drop of 0.002% OMDI in one randomly selected eye and placebo in the contralateral eye once daily. IOP, PD, and conjunctival hyperemia scores were measured five times daily during the baseline (3 days), treatment (5 days), and recovery (3 days) periods.
resultsA single instillation of topical OMDI significantly lowered IOP by a maximal IOP reduction of 7.2 mmHg (60%). In the repeated-dose study, once-daily administration of topical OMDI significantly reduced average daily IOP ± SD by 4.8 ± 0.68 mmHg (38.6%) and 6.1 ± 0.75 mmHg (44.3%), relative to baseline and contralateral controls, respectively. No clinically relevant miosis was observed in OMDI-treated eyes. Adverse events were limited to mild-to-moderate conjunctival hyperemia in OMDI-treated eyes.
conclusionsOnce-daily administration of 0.002% OMDI resulted in a robust reduction in IOP without inducing miosis and was well-tolerated in normal dogs. Further studies are warranted to assess its therapeutic potential and long-term safety in dogs with glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.